Skip to content

Advertisement

  • Poster presentation
  • Open Access

Design, method and application of stopping rules in a phase III 2x2 factorial randomised controlled trial

  • 1,
  • 1 and
  • 2
Trials201516 (Suppl 2) :P207

https://doi.org/10.1186/1745-6215-16-S2-P207

  • Published:

Keywords

  • Prednisolone
  • Factorial Design
  • Pentoxifylline
  • Treatment Interaction
  • Alcoholic Hepatitis

Background

The STOPAH trial was a double-blind, 2x2 factorial, phase III randomised clinical trial assessing the treatment of prednisolone and pentoxifylline in patients with severe alcoholic hepatitis; a study that aimed to evaluate 28-day mortality [1].

At the time of trial development, the benefits/harms of pentoxifylline in this patient population were unknown. Prednisolone had a significant though uncertain evidence base. No treatment interaction was assumed yet there was uncertainty about its effect. Therefore, pre-specified stopping rules to assist decision making in stopping treatment arms were required.

Methods

There was no published methodology on stopping rules for factorial trials, so a design based on the Peto-Haybittle [2] rule was created. Logistic regression modelling 28-day mortality, adjusting for factorial design, was to be produced at interim time points. Treatment arms were to be stopped if the two-sided p-value was <0.001. Both benefit and harm (symmetrical stopping boundary) treatment effects were evaluated. This conservative method was formulated because the treatments were already in practice and so convincing evidence to stop early was needed. The treatment interaction of prednisolone and pentixoifylline was assessed at the 10% significance level. If significant, the factorial design assumption was to be removed prior to interim analysis. The stopping rules would then be applied as described.

Application

An independent data monitoring committee assessed these stopping rules after 200, 400 and 800 patients had reached the primary endpoint. The stopping rules were not met at any of the three interim looks. The results of the STOPAH trial have recently been published [3].

Authors’ Affiliations

(1)
Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
(2)
Imperial College, London, UK

References

  1. Forrest , et al: Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials. 2013, 14: 262-View ArticlePubMedPubMed CentralGoogle Scholar
  2. Pocock SJ: Current controversies in data monitoring for clinical trials. Clin Trials. 2006, 3: 513-View ArticlePubMedGoogle Scholar
  3. Thursz , et al: Prednisolone or Pentoxifylline for Alcoholic Hepatitis. N Engl J Med. 2015, 372: 1619-1628.View ArticlePubMedGoogle Scholar

Copyright

© Bowers et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement